Trust Chemists and Druggists Private Limited has raised equity
Trust Chemists and Druggists Private Limited has successfully completed an equity raise.
Founded in 2003, Trust Chemists and Druggists operates one of the largest hospital pharmacy chains in India. Specializing in managing in-hospital pharmacies, the company operates 47 in-hospital stores and 14 standalone stores across Karnataka, Tamil Nadu and Andhra Pradesh. It offers a one-stop shop for all medicines and wellness needs.
Oaklins’ team in India provided strategic and financial advisory services throughout this transaction. The team onboarded an investor, a family office, adding strategic value and contributing to financial growth. This investor acquired a 26% fully diluted stake in the investee.
Talk to the deal team
Related deals
Bolster Investment Partners has acquired a majority stake in Eternal Sun
Bolster Investment Partners, a Netherlands-based investment firm, has acquired a majority stake in Eternal Sun, a global technology leader in advanced solar panel testing equipment, from ABN AMRO Sustainable Impact Fund, a private impact fund based in the Netherlands, and Vermec, a Belgium-based investment firm.
Learn moreCerbios-Pharma has been acquired by HAS Healthcare
Cerbios-Pharma S.A. has been acquired by HAS Healthcare Advanced Synthesis S.A., forming a leading global contract development and manufacturing organization (CDMO) group. This transaction results in a seamless integration of complementary capabilities, combining extensive expertise in production, chemical and biological sciences and technical excellence, all designed to meet the evolving demands of the global pharmaceutical sector.
Learn moreiwell raises US$31 million to deploy its leading European smart battery storage solutions into new markets
iwell, a developer of smart energy management (EMS) and battery storage systems (BESS), has successfully closed a US$31 million (€27 million) funding round. The round was led by Meridiam, with Invest-NL and Rabobank participating, alongside existing investors.
Learn more